nach oben

Digestive Diseases and Sciences

Erschienen in:

29.03.2022 | Review

Primary Bariatric Procedures

verfasst von: Pichamol Jirapinyo, Christopher C. Thompson

Erschienen in: Digestive Diseases and Sciences | Ausgabe 5/2022

Einloggen, um Zugang zu erhalten

Abstract

Obesity is pandemic. It is estimated that by 2030, half of the U.S. population will have obesity. Current treatment options for obesity includes lifestyle modification, pharmacotherapy, endoscopic bariatric and metabolic therapy (EBMT) and bariatric surgery. Over the past decades, an increasing number of EBMTs have been developed and become available. As a gastroenterologist, it is therefore important to become familiar with the available EBMTs as well as their safety and efficacy profiles in order to educate and expeditiously refer patients for the appropriate therapy when eligible. This chapter will review currently available and upcoming EBMTs. Details on how the procedures are performed, their mechanisms of action as well as data from pivotal studies will be summarized.

WHO | Overweight and obesity. https://www.who.int/gho/ncd/risk_factors/overweight/en/. Accessed 3 May 2020.

Hales CM, Carroll MD, Fryar CD, et al. Prevalence of obesity and severe obesity among adults: United States, 2017–2018. NCHS Data Brief 2020(360);1–8.

Ward ZJ, Bleich SN, Cradock AL, et al. Projected U.S. state-level prevalence of adult obesity and severe obesity. N Engl J Med 2019;381:2440–2450.PubMedCrossRef

Cawley J, Meyerhoefer C. The medical care costs of obesity: an instrumental variables approach. J Health Econ 2012;31:219–230.PubMedCrossRef

Defining Adult Overweight & Obesity | Overweight & Obesity | CDC. https://www.cdc.gov/obesity/adult/defining.html. Published 28 April 2021. Accessed 26 May 2021.

Muniraj T, Day LW, Teigen LM, et al. AGA clinical practice guidelines on intragastric balloons in the management of obesity. Gastroenterology 2021;160:1799–1808.PubMedCrossRef

Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation 2014;129:S102–138.PubMedCrossRef

Look AHEAD Research Group. Eight-year weight losses with an intensive lifestyle intervention: the look AHEAD study. Obes Silver Spring Md 2014;22:5–13.CrossRef

Sjöström L, Lindroos A-K, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004;351:2683–2693.PubMedCrossRef

10.

Buchwald H, Oien DM. Metabolic/bariatric surgery worldwide 2011. Obes Surg 2013;23:427–436.PubMedCrossRef

11.

Sullivan S, Edmundowicz SA, Thompson CC. Endoscopic bariatric and metabolic therapies: new and emerging technologies. Gastroenterology 2017;152:1791–1801.PubMedCrossRef

12.

Jirapinyo P, Thompson CC. Endoscopic bariatric and metabolic therapies: surgical analogues and mechanisms of action. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc 2017;15:619–630.

13.

ASGE/ASMBS Task Force on Endoscopic Bariatric Therapy, Ginsberg GG, Chand B, et al. A pathway to endoscopic bariatric therapies. Gastrointest Endosc 2011;74:943–953.CrossRef

14.

ASGE/ASMBS Task Force on Endoscopic Bariatric Therapy. A pathway to endoscopic bariatric therapies. Surg Obes Relat Dis Off J Am Soc Bariatr Surg 2011;7:672–682.

15.

Nieben OG, Harboe H. Intragastric balloon as an artificial bezoar for treatment of obesity. Lancet Lond Engl 1982;1:198–199.CrossRef

16.

Hogan RB, Johnston JH, Long BW, et al. A double-blind, randomized, sham-controlled trial of the gastric bubble for obesity. Gastrointest Endosc 1989;35:381–385.PubMedCrossRef

17.

Shah R, Davitkov P, Abu Dayyeh BK, et al. AGA technical review on intragastric balloons in the management of obesity. Gastroenterology 2021;160:1811–1830.PubMedCrossRef

18.

Mion F, Napoléon B, Roman S, et al. Effects of intragastric balloon on gastric emptying and plasma ghrelin levels in non-morbid obese patients. Obes Surg 2005;15:510–516.PubMedCrossRef

19.

Dayyeh BKA, Woodman G, Acosta A, et al. 380 baseline gastric emptying and its change in response to diverse endoscopic bariatric therapies predict weight change after intervention. Gastroenterology 2016;150:S86.CrossRef

20.

Dayyeh BKA, Eaton LL, Woodman G, et al. 444 A randomized, multi-center study to evaluate the safety and effectiveness of an intragastric balloon as an adjunct to a behavioral modification program, in comparison with a behavioral modification program alone in the weight management of obese subjects. Gastrointest Endosc 2015;81:AB147.CrossRef

21.

Courcoulas A, Abu Dayyeh BK, Eaton L, et al. Intragastric balloon as an adjunct to lifestyle intervention: a randomized controlled trial. Int J Obes 2005 2017;41:427–433.

22.

Vargas EJ, Pesta CM, Bali A, et al. Single fluid-filled intragastric balloon safe and effective for inducing weight loss in a real-world population. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc 2018;16:1073–1080.e1.

23.

ASGE Bariatric Endoscopy Task Force and ASGE Technology Committee, Abu Dayyeh BK, Kumar N, et al. ASGE Bariatric Endoscopy Task Force systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting endoscopic bariatric therapies. Gastrointest Endosc 2015;82:425–438.e5.CrossRef

24.

Ponce J, Quebbemann BB, Patterson EJ. Prospective, randomized, multicenter study evaluating safety and efficacy of intragastric dual-balloon in obesity. Surg Obes Relat Dis Off J Am Soc Bariatr Surg 2013;9:290–295.CrossRef

25.

Ponce J, Woodman G, Swain J, et al. The REDUCE pivotal trial: a prospective, randomized controlled pivotal trial of a dual intragastric balloon for the treatment of obesity. Surg Obes Relat Dis Off J Am Soc Bariatr Surg 2015;11:874–881.CrossRef

26.

Agnihotri A, Xie A, Bartalos C, et al. Real-world safety and efficacy of fluid-filled dual intragastric balloon for weight loss. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc 2018;16:1081–1088.e1.

27.

Mion F, Ibrahim M, Marjoux S, et al. Swallowable Obalon^® gastric balloons as an aid for weight loss: a pilot feasibility study. Obes Surg 2013;23:730–733.PubMedCrossRef

28.

Sullivan S, Swain JM, Woodman G, et al. 812d The Obalon swallowable 6-month balloon system is more effective than moderate intensity lifestyle therapy alone: results from a 6-month randomized sham controlled trial. Gastroenterology 2016;150:S1267.CrossRef

29.

Moore RL, Seger MV, Garber SM, et al. Clinical safety and effectiveness of a swallowable gas-filled intragastric balloon system for weight loss: consecutively treated patients in the initial year of U.S. commercialization. Surg Obes Relat Dis Off J Am Soc Bariatr Surg 2019;15:417–423.CrossRef

30.

Machytka E, Klvana P, Kornbluth A, et al. Adjustable intragastric balloons: a 12-month pilot trial in endoscopic weight loss management. Obes Surg 2011;21:1499–1507.PubMedPubMedCentralCrossRef

31.

Dayyeh BKA, Noar MD, Lavin T, et al. 176 Pivotal randomized-controlled trial of the adjustable (SPATZ-3) intragastric balloon system for weight loss. Gastrointest Endosc 2019;89:AB58–AB59.CrossRef

32.

Ienca R, Al Jarallah M, Caballero A, et al. The procedureless elipse gastric balloon program: multicenter experience in 1770 consecutive patients. Obes Surg 2020;30:3354–3362.PubMedPubMedCentralCrossRef

33.

Ramai D, Singh J, Mohan BP, et al. Influence of the elipse intragastric balloon on obesity and metabolic profile: a systematic review and meta-analysis. J Clin Gastroenterol 2021;55(10):36–841.CrossRef

34.

Thompson CC, Slattery J, Bundga ME, et al. Peroral endoscopic reduction of dilated gastrojejunal anastomosis after Roux-en-Y gastric bypass: a possible new option for patients with weight regain. Surg Endosc 2006;20:1744–1748.PubMedCrossRef

35.

Fogel R, De Fogel J, Bonilla Y, et al. Clinical experience of transoral suturing for an endoluminal vertical gastroplasty: 1-year follow-up in 64 patients. Gastrointest Endosc 2008;68:51–58.PubMedCrossRef

36.

Devière J, Ojeda Valdes G, Cuevas Herrera L, et al. Safety, feasibility and weight loss after transoral gastroplasty: first human multicenter study. Surg Endosc 2008;22:589–598.PubMedCrossRef

37.

Familiari P, Costamagna G, Bléro D, et al. Transoral gastroplasty for morbid obesity: a multicenter trial with a 1-year outcome. Gastrointest Endosc 2011;74:1248–1258.PubMedCrossRef

38.

Brethauer SA, Chand B, Schauer PR, et al. Transoral gastric volume reduction for weight management: technique and feasibility in 18 patients. Surg Obes Relat Dis Off J Am Soc Bariatr Surg 2010;6:689–694.CrossRef

39.

Brethauer SA, Chand B, Schauer PR, et al. Transoral gastric volume reduction as intervention for weight management: 12-month follow-up of TRIM trial. Surg Obes Relat Dis Off J Am Soc Bariatr Surg 2012;8:296–303.CrossRef

40.

Kumar N, Sahdala HNP, Shaikh S, et al. Mo1155 Endoscopic sleeve gastroplasty for primary therapy of obesity: initial human cases. Gastroenterology 2014;146:S-571-S-572.CrossRef

41.

Abu Dayyeh BK, Rajan E, Gostout CJ. Endoscopic sleeve gastroplasty: a potential endoscopic alternative to surgical sleeve gastrectomy for treatment of obesity. Gastrointest Endosc 2013;78:530–535.PubMedCrossRef

42.

Sharaiha RZ, Kedia P, Kumta N, et al. Initial experience with endoscopic sleeve gastroplasty: technical success and reproducibility in the bariatric population. Endoscopy 2015;47:164–166.PubMed

43.

Lopez-Nava G, Sharaiha RZ, Vargas EJ, et al. Endoscopic sleeve gastroplasty for obesity: a multicenter study of 248 patients with 24 months follow-up. Obes Surg 2017;27:2649–2655.PubMedCrossRef

44.

Alqahtani A, Al-Darwish A, Mahmoud AE, et al. Short-term outcomes of endoscopic sleeve gastroplasty in 1000 consecutive patients. Gastrointest Endosc 2019;89:1132–1138.PubMedCrossRef

45.

Sharaiha RZ, Hajifathalian K, Kumar R, et al. Five-year outcomes of endoscopic sleeve gastroplasty for the treatment of obesity. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2020;19:1051–1057.

46.

Barrichello S, Hourneaux de Moura DT, Hourneaux de Moura EG, et al. Endoscopic sleeve gastroplasty in the management of overweight and obesity: an international multicenter study. Gastrointest Endosc 2019;90:770–780.PubMedCrossRef

47.

Hedjoudje A, Dayyeh BA, Cheskin LJ, et al. Efficacy and safety of endoscopic sleeve gastroplasty: a systematic review and meta-analysis. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc 2019;18:1043–1053.

48.

Abu Dayyeh BK, Acosta A, Camilleri M, et al. Endoscopic sleeve gastroplasty alters gastric physiology and induces loss of body weight in obese individuals. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc 2017;15:37–43.e1.

49.

Sullivan S, Swain JM, Woodman G, et al. 100 12 Month randomized Sham controlled trial evaluating the safety and efficacy of targeted use of endoscopic suture anchors for primary obesity: the ESSENTIAL study. Gastroenterology 2016;150:S25–S26.CrossRef

50.

Espinós JC, Turró R, Mata A, et al. Early experience with the Incisionless Operating Platform™ (IOP) for the treatment of obesity: the Primary Obesity Surgery Endolumenal (POSE) procedure. Obes Surg 2013;23:1375–1383.PubMedCrossRef

51.

Miller K, Turró R, Greve JW, et al. MILEPOST multicenter randomized controlled trial: 12-month weight loss and satiety outcomes after pose SM versus medical therapy. Obes Surg 2017;27:310–322.PubMedCrossRef

52.

Singh S, Bazarbashi AN, Khan A, et al. Primary obesity surgery endoluminal (POSE) for the treatment of obesity: a systematic review and meta-analysis. Surg Endosc. 2021;36:252–266.PubMedCrossRef

53.

Jirapinyo P, Thompson CC. Gastric plications for weight loss: distal primary obesity surgery endoluminal through a belt-and-suspenders approach. VideoGIE Off Video J Am Soc Gastrointest Endosc 2018;3:296–300.

54.

Jirapinyo P, Thompson CC. Endoscopic gastric body plication for the treatment of obesity: technical success and safety of a novel technique (with video). Gastrointest Endosc 2020;91:1388–1394.PubMedPubMedCentralCrossRef

55.

Lopez Nava G, Asokkumar R, Laster J, et al. Primary obesity surgery endoluminal (POSE-2) procedure for treatment of obesity in clinical practice. Endoscopy 2020;53:1169–1173.PubMed

56.

Espinós JC, Turró R, Moragas G, et al. Gastrointestinal physiological changes and their relationship to weight loss following the POSE procedure. Obes Surg 2016;26:1081–1089.PubMedCrossRef

57.

Lopez-Nava G, Asokkumar R, Rull A, et al. Safety and feasibility of a novel endoscopic suturing device (EndoZip TM) for treatment of obesity: first-in-human study. Obes Surg 2020;30:1696–1703.PubMedCrossRef

58.

Huberty V, Machytka E, Boškoski I, et al. Endoscopic gastric reduction with an endoluminal suturing device: a multicenter prospective trial with 1-year follow-up. Endoscopy 2018;50:1156–1162.PubMedCrossRef

59.

Huberty V, Boskoski I, Bove V, et al. Endoscopic sutured gastroplasty in addition to lifestyle modification: short-term efficacy in a controlled randomised trial. Gut 2020;70:1479–1485.CrossRef

60.

First clinical experience with the TransPyloric Shuttle (TPS(r)) device, a non-surgical endoscopic treatment for obesity: results from a 3-month and 6-month study—SAGES abstract archives. SAGES. http://www.sages.org/meetings/annual-meeting/abstracts-archive/first-clinical-experience-with-the-transpyloric-shuttle-tpsr-device-a-non-surgical-endoscopic-treatment-for-obesity-results-from-a-3-month-and-6-month-study/. Accessed 16 July 2016.

61.

T-P-3277 | Weight reduction in patients with obesity using the TransPyloric Shuttle^®: ENDObesity^® II Study—ObesityWeek 2018 | #OW2018. https://2018.obesityweek.com/abstract/weight-reduction-in-patients-with-obesity-using-the-transpyloric-shuttle-endobesity-ii-study/. Accessed 28 Oct 2019.

62.

Sullivan S, Stein R, Jonnalagadda S, et al. Aspiration therapy leads to weight loss in obese subjects: a pilot study. Gastroenterology 2013;145:1245–1252.e1–5.PubMedCrossRef

63.

Thompson CC, Dayyeh BKA, Kushner R, et al. 381 The AspireAssist is an effective tool in the treatment of class II and class III obesity: results of a 1-year clinical trial. Gastroenterology 2016;150:S86.CrossRef

64.

Thompson CC, Abu Dayyeh BK, Kushnir V, et al. Aspiration therapy for the treatment of obesity: 4-year results of a multicenter randomized controlled trial. Surg Obes Relat Dis Off J Am Soc Bariatr Surg 2019;15:1348–1354.CrossRef

65.

Jirapinyo P, Kumar N, Saumoy M, et al. Association for Bariatric Endoscopy systematic review and meta-analysis assessing the American Society for Gastrointestinal Endoscopy Preservation and Incorporation of Valuable Endoscopic Innovations thresholds for aspiration therapy. Gastrointest Endosc 2021;93:334–342.e1.PubMedCrossRef

66.

McIntosh CHS, Widenmaier S, Kim S-J. Glucose-dependent insulinotropic polypeptide (Gastric Inhibitory Polypeptide; GIP). Vitam Horm 2009;80:409–471.PubMedCrossRef

67.

Punjabi M, Arnold M, Geary N, et al. Peripheral glucagon-like peptide-1 (GLP-1) and satiation. Physiol Behav 2011;105:71–76.PubMedCrossRef

68.

Meek CL, Lewis HB, Reimann F, et al. The effect of bariatric surgery on gastrointestinal and pancreatic peptide hormones. Peptides 2016;77:28–37.PubMedCrossRef

69.

Rodriguez-Grunert L, Galvao Neto MP, Alamo M, et al. First human experience with endoscopically delivered and retrieved duodenal-jejunal bypass sleeve. Surg Obes Relat Dis Off J Am Soc Bariatr Surg 2008;4:55–59.CrossRef

70.

Rohde U, Hedbäck N, Gluud LL, et al. Effect of the EndoBarrier gastrointestinal liner on obesity and type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab 2016;18:300–305.PubMedCrossRef

71.

Jirapinyo P, Haas AV, Thompson CC. Effect of the duodenal-jejunal bypass liner on glycemic control in patients with type 2 diabetes with obesity: a meta-analysis with secondary analysis on weight loss and hormonal changes. Diabetes Care 2018;41:1106–1115.PubMedCrossRef

72.

Rajagopalan H, Cherrington AD, Thompson CC, et al. Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes: 6-month interim analysis from the first-in-human proof-of-concept study. Diabetes Care 2016;39(12):2254–2261.PubMedCrossRef

73.

van Baar ACG, Holleman F, Crenier L, et al. Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes mellitus: 1 year results from the first international, open-label, prospective, multicentre study. Gut 2019;69:295–303.PubMedCrossRef

74.

de Oliveira GHP, de Moura DTH, Funari MP, et al. Metabolic effects of endoscopic duodenal mucosal resurfacing: a systematic review and meta-analysis. Obes Surg 2021;31:1304–1312.PubMedCrossRef

75.

Machytka E, Bužga M, Zonca P, et al. Partial jejunal diversion using an incisionless magnetic anastomosis system: 1-year interim results in patients with obesity and diabetes. Gastrointest Endosc 2017;86:904–912.PubMedCrossRef

76.

Sauer N, Rösch T, Pezold J, et al. A new endoscopically implantable device (SatiSphere) for treatment of obesity–efficacy, safety, and metabolic effects on glucose, insulin, and GLP-1 levels. Obes Surg 2013;23:1727–1733.PubMedCrossRef

77.

Cooper Z, Cooper PJ, Fairburn CG. The validity of the eating disorder examination and its subscales. Br J Psychiatry J Ment Sci 1989;154:807–812.CrossRef

78.

Cooper Z, Fairburn C. Eating disorder examination. September 2011. http://doi.apa.org/getdoi.cfm?doi=10.1037/t03975-000. Accessed 24 May 2020.

79.

Jirapinyo P, Thompson CC. Training in bariatric and metabolic endoscopic therapies. Clin Endosc 2018;51:430–438.PubMedPubMedCentralCrossRef

80.

Jirapinyo P, Thompson CC. How to incorporate bariatric training into your fellowship program. Gastroenterology 2019;157:9–13.PubMedCrossRef

Titel: Primary Bariatric Procedures
verfasst von: Pichamol Jirapinyo
Christopher C. Thompson
Publikationsdatum: 29.03.2022
Verlag: Springer US
Erschienen in: Digestive Diseases and Sciences / Ausgabe 5/2022
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-022-07393-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Primary Bariatric Procedures

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2022

Does Surveillance Increase Survival? Benefits of Periodic Colonoscopy in Patients with Ulcerative Colitis and Colorectal Cancer

Experimental Intestinal Stenosis Alters Crohn’s Disease-Like Intestinal Inflammation in Ileitis-Prone Mice

Risk of Delayed Bleeding after Cold Snare Polypectomy in Patients with Antithrombotic Therapy

When ERCP Fails: EUS-Guided Access to Biliary and Pancreatic Ducts

Gastrointestinal Computed Tomography Findings in Chronic Granulomatous Disease with Subgroup Clinicopathologic Analysis

Intestinal Failure in Junctional Epidermolysis Bullosa: Mild Skin Disease, Severe Diarrhea

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin